|Product Name||Mouse TRANCE/TNFSF11/RANKL ELISA Kit|
|Customs Name||Mouse TRANCE/TNFSF11/RANKL ELISA Kit|
|Assay Type||Sandwich ELISA|
|Suitable Sample Type||serum, plasma, cell culture supernates|
|Format||96-well strip plate|
|Storage||4℃ (unopened) standard stored at -20℃, others stored at 4℃ (opened)|
|Sample Volume||20 μl|
|Standard Curve Range||31.25 - 2000 pg/ml|
|Spike Recovery Range||85 % - 118 %|
|Mean Spike Recovery||0.94|
|CV of Intra plate||2.9 % - 7.9 %|
|CV of Inter plate||3.1 % - 5.4 %|
|Components||96-well polystyrene microplate coated with a monoclonal antibody against IL-22
Mouse IL-22 Standard, lyophilized
IL-22 Detect Antibody
Assay Buffer (10×)
washing Buffer (20×)
|Describtion||This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of mouse TRANCE. The Mouse TRANCE/TNFSF11/RANKL ELISA is for research use only. Not for diagnostic or therapeutic procedures.
TNF-related activation-induced cytokine (TRANCE), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), receptor activator of nuclear factor kappa-B ligand (RANKL), is a member of the TNF superfamily. Cells known to express TRANCE include osteoblasts, CD4+ and CD8+ T cells, megakaryocytes, bronchial and intestinal epithelium and so on.
TRANCE appears to play a central role in both immune response and bone morphogenesis. During bone development and remodeling, TRANCE expression by osteoblasts in conjunction with M-CSF induces osteoclast formation and activation, resulting in bone resorption. This allows for subsequent bone deposition and remodeling. TRANCE also plays a role in pathological osteoporosis. Its inappropriate expression by activated lymphocytes and osteoblasts results in excessive joint and bone resorption vs. deposition. Overproduction of TRANCE is implicated in a variety of degenerative bone diseases, such as rheumatoid arthritis and psoriatic arthritis.